


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-2 are cancelled.

3. (currently amended) A stereochemically pure protease inhibitor represented by the following structure:




wherein

R₁ is a radical selected from the group consisting of carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-alanine-asparagine- and carbobenzyloxy-valine-valine-; and

R₂ is a radical selected from the group consisting of ~~-(H)₂~~, and ~~H(t-Butyl)~~
-H and -(t-Butyl).

Claims 4-5 are cancelled.

6. (once amended) A protease inhibitor represented by the following structure:




wherein

R₁ is selected from the group consisting of carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-alanine-asparagine-, carbobenzyloxy-threonine-valine- and carbobenzyloxy-valine-valine-;


R₂ is selected from the group consisting of -CH₂-Phenyl, and -CH₂-CH(CH₃)₂;

R₇ is a radical represented by the formula:




wherein R₈ is a radical selected from the group consisting of -(H)₂, and -H(t-Butyl).

7. (unamended) A protease inhibitor according to claim 6 represented by the following structure:



8. (once amended) A protease inhibitor represented by the following structure:




wherein

R_1 is selected from the group consisting of carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-alanine-asparagine-, carbobenzyloxy-threonine-valine- and carbobenzyloxy-valine-valine-;


R_2 is selected from the group consisting of $-\text{CH}_2\text{-Phenyl}$, and $-\text{CH}_2\text{-CH}(\text{CH}_3)_2$;

R_7 is a radical represented by the formula:




wherein R_8 is a radical selected from the group consisting of $-(\text{H})_2$, and $-\text{H}(\text{t-Butyl})$.

9. (unamended) A protease inhibitor according to claim 8 represented by the following structure:




Claim 10 is cancelled.

11. (currently amended) A stereochemically pure protease inhibitor represented by the following structure:




Claims 12-15 are cancelled.


16. (once amended) A protease inhibitor represented by the following structure:




17. (once amended) A protease inhibitor represented by the following structure:



18. (currently amended) A stereochemically pure protease inhibitor according to claim 3 represented by the following structure:




19. (once amended) A protease inhibitor represented by the following structure:




wherein R_1 is a radical selected from the group consisting of carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-valine-valine- and carbobenzyloxy-alanine-asparagine-.

20. (unamended) A protease inhibitor according to claim 19 represented by the following structure:




21. (once amended) A protease inhibitor represented by the following structure:



wherein R_1 is a radical selected from the group consisting of carbobenzyloxy-valine-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-valine-valine- and carbobenzyloxy-alanine-asparagine-.

22. (unamended) A protease inhibitor according to claim 21 represented by the following structure:



Claim 23 is cancelled.